Standardized Frozen Preparation for Transplantation of Fecal Microbiota for Recurrent Clostridium difficile Infection
By M. Hamilton, Alexa R. Weingarden, M. Sadowsky, A. Khoruts. American Journal of Gastroenterology, 2012
703 citations recorded by the source corpus.
Subfields: Gastroenterology, Infectious Diseases, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/1c49c30cc9c83bbcd4edda720f8ffd01c84b1e68
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Molecular Biology
Citations in the corpus
- European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. (2014, background): “[177] Faecal enema 27 7 427 days [178] 5/27 patients had two FT: 2/5 failures Faecal instillation through coloscope Patients with (14) and without (29) IBD.”
- Factors affecting the composition of the gut microbiota, and its modulation (2019, background): “Currently, researchers do not agree on the efficacy of probiotics in intestinal diseases, largely because studies have used different doses and types of probiotics (Ringel & RingelKulka, 2011; Hamilton et al., 2012; Borody et al., 2004).”
- Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study (2017, methodology): “Lastly, a larger sample size will be essential to clarify associations with other variables, such as the efficacy of oral versus rectal administration of the SHGM.”
- Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. (2016, background): “Antibiotic use prior to first FMT 58 (13-645) 43.”
- Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial (2019, neutral): “5 (28-52) 35 (25-46) Duration of disease, median (IQR), y 4.”